Literature DB >> 21680679

Can sequential 18F-FDG PET/CT replace WBC imaging in the diabetic foot?

Demetrio Familiari1, Andor W J M Glaudemans, Valeria Vitale, Daniela Prosperi, Oreste Bagni, Andrea Lenza, Marco Cavallini, Francesco Scopinaro, Alberto Signore.   

Abstract

UNLABELLED: White blood cell (WBC) scintigraphy is considered the nuclear medicine imaging gold standard for diagnosing osteomyelitis in the diabetic foot. Recent papers have suggested that the use of (18)F-FDG PET/CT produces similar diagnostic accuracy, but clear interpretation criteria have not yet been established. Our aim was to evaluate the role of sequential (18)F-FDG PET/CT in patients with a high suspicion of osteomyelitis to define objective interpretation criteria to be compared with WBC scintigraphy.
METHODS: Thirteen patients whom clinicians considered positive for osteomyelitis (7 with ulcers, 6 with exposed bone) were enrolled. The patients underwent (99m)Tc-exametazime WBC scintigraphy with acquisition times of 30 min, 3 h, and 20 h and sequential (18)F-FDG PET/CT with acquisition times of 10 min, 1 h, and 2 h. A biopsy or tissue culture was performed for final diagnosis. Several interpretation criteria (qualitative and quantitative) were tested.
RESULTS: At final biopsy, 7 patients had osteomyelitis, 2 had soft-tissue infection without osteomyelitis, and 4 had no infection. The best interpretation criterion for osteomyelitis with WBC scintigraphy was a target-to-background (T/B) ratio greater than 2.0 at 20 h and increasing with time. A T/B ratio greater than 2.0 at 20 h but stable or decreasing with time was suggestive of soft-tissue infection. A T/B ratio of no more than 2.0 at 20 h excluded an infection. Thus, sensitivity, specificity, positive predictive value, negative predictive value, and accuracy for osteomyelitis were 86%, 100%, 100%, 86%, and 92%, respectively. For (18)F-FDG PET/CT, the best interpretation criterion for osteomyelitis was a maximal standardized uptake value (SUVmax) greater than 2.0 at 1 and 2 h and increasing with time. A SUVmax greater than 2.0 after 1 and 2 h but stable or decreasing with time was suggestive of a soft-tissue infection. An SUVmax less than 2.0 excluded an infection. (18)F-FDG PET at 10 min was not useful. Using these criteria, sensitivity, specificity, positive predictive value, negative predictive value, and accuracy for osteomyelitis were 43%, 67%, 60%, 50%, and 54%, respectively. Combining visual assessment of PET at 1 h and CT was best for differentiating between osteomyelitis and soft-tissue infection, with a diagnostic accuracy of 62%.
CONCLUSION: (18)F-FDG PET/CT, even with sequential imaging, has a low diagnostic accuracy for osteomyelitis and cannot replace WBC scintigraphy in patients with diabetic foot.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21680679     DOI: 10.2967/jnumed.110.082222

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  27 in total

1.  The diagnostic value of [(18)F]FDG PET for the detection of chronic osteomyelitis and implant-associated infection.

Authors:  Vera Wenter; Jan-Phillip Müller; Nathalie L Albert; Sebastian Lehner; Wolfgang P Fendler; Peter Bartenstein; Clemens C Cyran; Jan Friederichs; Matthias Militz; Marcus Hacker; Sven Hungerer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-11-07       Impact factor: 9.236

2.  (18)F-FDG PET and PET/CT for the diagnosis of diabetic foot osteomyelitis.

Authors:  N Papanas; A Zissimopoulos; E Maltezos
Journal:  Hippokratia       Date:  2013-01       Impact factor: 0.471

3.  Image acquisition and interpretation criteria for 99mTc-HMPAO-labelled white blood cell scintigraphy: results of a multicentre study.

Authors:  Paola A Erba; Andor W J M Glaudemans; Niels C Veltman; Martina Sollini; Marta Pacilio; Filippo Galli; Rudi A J O Dierckx; Alberto Signore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-11-26       Impact factor: 9.236

4.  Vasculo-Behçet disease complicated by conversion disorder diagnosed with 18F-fluoro-deoxy-glucose positron emission tomography combined with computed tomography (PET/CT).

Authors:  Makiko Yashiro Furuya; Jumpei Temmoku; Yuya Fujita; Naoki Matsuoka; Tomoyuki Asano; Shuzo Sato; Hiroko Kobayashi; Hiroshi Watanabe; Kiyoshi Migita
Journal:  Fukushima J Med Sci       Date:  2019-07-20

5.  Diagnosis of infection in the diabetic foot using (18)F-FDG PET/CT: a sweet alternative?

Authors:  Gopinath Gnanasegaran; Sanjay Vijayanathan; Ignac Fogelman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-10       Impact factor: 9.236

6.  Guidelines for the use of 18F-FDG in infection and inflammation: a new step in cooperation between the EANM and SNMMI.

Authors:  J Buscombe
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-07       Impact factor: 9.236

7.  FDG PET/CT imaging in the diagnosis of osteomyelitis in the diabetic foot.

Authors:  Olga Kagna; Saher Srour; Eyal Melamed; Daniela Militianu; Zohar Keidar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-07-17       Impact factor: 9.236

Review 8.  Clinical Applications for Radiotracer Imaging of Lower Extremity Peripheral Arterial Disease and Critical Limb Ischemia.

Authors:  Ting-Heng Chou; Mitchel R Stacy
Journal:  Mol Imaging Biol       Date:  2020-04       Impact factor: 3.488

9.  [18F]FDG PET/CT in non-union: improving the diagnostic performances by using both PET and CT criteria.

Authors:  Martina Sollini; Nicoletta Trenti; Emiliano Malagoli; Marco Catalano; Lorenzo Di Mento; Alexander Kirienko; Marco Berlusconi; Arturo Chiti; Lidija Antunovic
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-05-01       Impact factor: 9.236

10.  A large retrospective single-centre study to define the best image acquisition protocols and interpretation criteria for white blood cell scintigraphy with ⁹⁹mTc-HMPAO-labelled leucocytes in musculoskeletal infections.

Authors:  Andor W J M Glaudemans; Erik F J de Vries; Liliane E M Vermeulen; Riemer H J A Slart; Rudi A J O Dierckx; Alberto Signore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-07-17       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.